About the Study
Genetics can sometimes explain why some people respond well to a drug whereas others may experience serious side effects. The InVite Study is a collaborative effort between 23andMe and Genentech to learn more about how genes influence response to bevacizumab (also known as Avastin®) in the treatment of metastatic breast cancer.
Join a new way of participating in research - fast, simple steps done in a place that is convenient for you. What do you have to do?
- Send in a saliva sample (collected in a 23andMe DNA kit)
- Take a baseline survey about your breast cancer diagnosis and experience on bevacizumab (also known as Avastin®)
- Answer short follow up questions every three months about any changes in your health or treatment
- Provide a blood sample -- this part of the study is recommended, but is not required for participation
This study does not involve any new or additional treatment for breast cancer. Participation in this study will not affect how you are treated by your physician for your breast cancer.
Have more questions? Check out our FAQs.
Who is Eligible
- Diagnosed with metastatic breast cancer (stage IV) or recurrent breast cancer by a medical professional
- Treated with bevacizumab (also known as Avastin®) starting on or before December 31, 2011
- Live in the United States
- Age 18 or older
*If you were treated with bevacizumab (also known as Avastin®) after 2011, and are interested in possible future opportunities to participate, please email
invite-study@23andme.com.
What You Get
- Convenient and easy opportunity to participate in new type of research
- Help advance medical research in metastatic breast cancer and its treatment
- Receive updates about research progress and discoveries
- Learn about your health and ancestry through FREE access to 23andMe's Personal Genome Service
23andMe Research
Get involved in a new way of doing research.
23andMe, a personal genetics company, is dedicated to accelerating the pace of research and making discoveries that lead to improved patient care. By combining participants' genetic data with survey responses about their health and experiences, we hope to discover new genetic markers for diseases, understand why some people respond to treatment more readily than others, and explore gene-environment interactions.
23andMe's innovative research model enables individuals to take an active role in research and their own healthcare. We have ongoing research projects in several disease areas, such as Parkinson's Disease, Sarcoma, and Myeloproliferative Neoplasms. Our Roots into the Future initiative involves recruiting 10,000 African Americans into a study to explore connections between DNA and disease in diverse ethnic groups. As a 23andMe member, you can contribute to research in a variety of other topics through online surveys on the main 23andMe website.
New to genetics?
Learn more about genetics and how it relates to health and ancestry. 23andMe provides a collection of educational materials to guide you on your personal journey of genetic discovery. Explore our learning resources and video tutorials on the main 23andMe website.
Bevacizumab is not approved by the FDA for the treatment of Breast Cancer. This study is for research purposes only.
For more information, go to http://www.gene.com/gene/products/information/oncology/avastin/